Members of the CIMT Monitoring Panel
The CIP committee is chaired by C. Britten (Mainz, Germany), C. Gouttefangeas (Tübingen, Germany) and S. van der Burg (Leiden, the Netherlands) who are responsible for coordinating and directing the CIP.
Participating Countries:
Members organizing CIP proficiency panels:
- S. Attig, Department of Internal Medicine III, University of Mainz, Mainz, Germany
- C. M. Britten, Department of Internal Medicine III, University of Mainz, Mainz, Germany
- S. H. van der Burg, Department for Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
- C. Gouttefangeas, Department of Immunology, University of Tuebingen, Tuebingen, Germany
- A. Letsch, Department of Hematology and Oncology, Charite, Berlin, Germany
- S.R. Hadrup, Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, Denmark
- T. M. S. Køllgaard, Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, Denmark
- A. Mander, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
- C. H. Ottensmeier, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
- M. J. P. Schoenmaekers-Welters, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands
Members participating in the proficiency panel program:
- E. Derhovanessian, Center for Medical Research, University of Tuebingen, Tuebingen, Germany
- M. Fassnacht, Department of Internal Medicine I, University of Wuerzburg, Wuerzburg, Germany
- K. Giannopoulos, Clinical Immunology Department, Medical University of Lublin, Lublin, Poland
- G. Gaudernack, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
- S. E. M. Inderberg, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
- E. Kaempgen, Department of Dermatology, University of Erlangen, Erlangen, Germany
- A. K. Kaskel, Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
- F. Kern, Division of Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom
- S. Koch, Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
- K. Lislerud, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
- L. Low, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
- A. Mackensen, Department of Haematology and Oncology, University of Regensburg, Regensburg, Germany
- R. Maier, Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
- A. Mesenholl, Mabtech, Nacka Strand, Sweden
- M. Navarette, Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
- A. Paschen, Skin Cancer Unit of the German Cancer Research Center, University Hospital Mannheim, Mannheim, Germany
- S. Paulie, Mabtech, Nacka Strand, Sweden
- G. Pawelec, Center for Medical Research, University of Tuebingen, Tuebingen, Germany
- H. Pohla, Tumor Immunology, University of Munich, Munich, Germany
- A. M Rasmussen, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
- D. Riemann, Institute of Medical Immunology, Martin Luther University, Halle, Germany
- R. Samorski, Immatics Biotechnologies, Tuebingen, Germany
- C. Scheibenbogen, Department of Hematology and Oncology, Charite, Berlin, Germany
- A. Schmitt, Department of Internal Medicine III, University of Rostock, Rostock, Germany
- M. Schmitt, Department of Internal Medicine III, University of Rostock, Rostock, Germany
- M. Schmitt-Haendle, Department. of Dermatology, University of Erlangen, Erlangen, Germany
- E. Schultz, Department of Dermatology, University of Marburg, Marburg, Germany
- B. Seliger, Institute of Medical Immunology, Martin Luther University, Halle, Germany
- D. Speiser, Ludwig Institute of Cancer Research, Lausanne, Switzerland
- S. Stevanović, Department of Immunology, University of Tuebingen, Tuebingen, Germany
- P. T. Straten, Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, Denmark
- A. Thiel, DRFZ, Berlin, Germany
- H. Veelken, Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
- S. Walter, Immatics Biotechnologies, Tuebingen, Germany
- M. Wiesinger, Department of Dermatology, University of Erlangen, Erlangen, Germany
- T. Wölfel, Department of Internal Medicine III, University Mainz, Mainz, Germany
Meeting of the group in Mai 2005
